Literature DB >> 3877250

Regulation of hexokinase in cultured gliomas.

J F Graham, C J Cummins, B H Smith, P L Kornblith.   

Abstract

Positron emission computed tomographic (PECT) scanning studies have demonstrated that high grade gliomas exhibit increased 2-[18F]fluoro-2-deoxyglucose (18FDG) uptake compared to cerebral white matter and low grade gliomas. Hexokinase catalyzes the phosphorylation of glucose, as well as 18FDG and 2-deoxyglucose (2DG), thereby "trapping" these slowly metabolized analogues intracellularly. We hypothesize that a similar hexokinase-mediated uptake of glucose and glucose analogues occurs in vitro. Hexokinase activity was assayed in homogenates of tissue-cultured lines derived from high (IV) and low (II) grade gliomas and in fibroblasts derived from skin. With glucose as substrate, the maximal activity (Vmax) in the Grade IV lines was 200% of the activity found in the Grade II line, fibroblasts, and astrocytes; however, the Michaelis substrate affinity constant (Km) bore no relationship to tumor grade. With 2DG as substrate, the Vmax of all cell lines decreased, but the Grade IV lines still tended to have greater activity than the others. The Km values for 2DG were 5 times higher than those for glucose. Hexokinase is found in two subcellular compartments: an active form reversibly bound to mitochondria and a less active, cytosolic form. Up to 20% of the total hexokinase was found in the cytosol in all lines tested. High energy phosphate compounds (ATP, ADP, CTP, and others) displaced mitochondria-bound hexokinase, which increased the cytosolic form by 2-fold in the glioma lines, but fibroblast hexokinase distribution was unaffected. Our results suggest that: (a) high grade gliomas have increased hexokinase activity, which may explain the grade-related differences in 18FDG uptake observed by PECT scanning, and (b) human glioma hexokinases may be regulated by reversible subcellular compartmentation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3877250     DOI: 10.1227/00006123-198510000-00001

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  9 in total

1.  Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.

Authors:  Cécile Colavolpe; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Béquet-Boucard; Dominique Figarella-Branger; Olivier Mundler; Olivier Chinot; Eric Guedj
Journal:  J Neurooncol       Date:  2011-12-15       Impact factor: 4.130

Review 2.  Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.

Authors:  Saroj P Mathupala; Young H Ko; Peter L Pedersen
Journal:  Semin Cancer Biol       Date:  2008-12-03       Impact factor: 15.707

3.  FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

Authors:  Cécile Colavolpe; Olivier Chinot; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Bequet-Boucard; Emeline Tabouret; Olivier Mundler; Dominique Figarella-Branger; Eric Guedj
Journal:  Neuro Oncol       Date:  2012-02-29       Impact factor: 12.300

Review 4.  Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria.

Authors:  S P Mathupala; Y H Ko; P L Pedersen
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

5.  Proton magnetic resonance spectroscopy (1H-MRS) for the evaluation of treatment of brain tumours.

Authors:  K Houkin; K Kamada; Y Sawamura; Y Iwasaki; H Abe; T Kashiwaba
Journal:  Neuroradiology       Date:  1995-02       Impact factor: 2.804

6.  FDG transport and phosphorylation in human gliomas measured with dynamic PET.

Authors:  K Herholz; J Rudolf; W D Heiss
Journal:  J Neurooncol       Date:  1992-02       Impact factor: 4.130

7.  The potential role of lonidamine (LND) in the treatment of malignant glioma. Phase II study.

Authors:  C M Carapella; M G Paggi; F Cattani; G B Ciottoli; A Floridi; B Iandolo; L Raus; A Riccio; A Caputo
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

8.  Localised proton spectroscopy and spectroscopic imaging in cerebral gliomas, with comparison to positron emission tomography.

Authors:  K G Go; R L Kamman; E L Mooyaart; M A Heesters; J Pruim; W Vaalburg; A M Paans
Journal:  Neuroradiology       Date:  1995-04       Impact factor: 2.804

9.  High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss.

Authors:  S Oudard; F Arvelo; L Miccoli; F Apiou; A M Dutrillaux; M Poisson; B Dutrillaux; M F Poupon
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.